Recent Updates
Recently added Catalysts
REPL Negative Sentiment

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Replimune Group, Inc. following a class action complaint filed against the company. The lawsuit, which pertains to the period between November 22, 2024, and July 21, 2025, alleges that Replimune made misleading statements about the prospects of its IGNYTE trial. This resulted in the FDA deeming the trial inadequate. The law firm is urging affected long-term stockholders to discuss their legal options.
Price reaction · baseline $4.65 (2025-10-07 close) · hit after-hours · clean, no other REPL news in the window
day 0 close · peak
-1.7%

Market Sentiment Analysis

CONCERNS & RISKS

  • Replimune has been implicated in a class action lawsuit regarding false statements.
  • The lawsuit claims the company overstated the IGNYTE trial's potential, leading to FDA concerns.
  • The board of directors may have breached their fiduciary duties to stockholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+816%
120-day peak, hindsight
Typical move
25.1%
average across 6 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
RP1
Phase 2 · Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
If you are a long-term stockholder in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Replimune Group, Inc. (NASDAQ:REPL) on behalf of long-term stockholders following a class action complaint that was filed against Replimune on July 24, 2025 with a Class Period from November 22, 2024 and July 21, 2025. Our investigation concerns whether the board of directors of Replimune have breached their fiduciary duties to the company.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you are a long-term stockholder of Replimune, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

How can I contact Bragar Eagel & Squire for Replimune issues?

You can call Brandon Walker or Marion Passmore at (212) 355-4648.

What is the class period for Replimune stockholders?

The class period for Replimune stockholders is from November 22, 2024, to July 21, 2025.

What claims are being investigated against Replimune?

The investigation concerns potential breaches of fiduciary duties by the Replimune board.

What issues were raised in the class action complaint?

The complaint alleges misleading statements about the IGNYTE trial, impacting investor information.

Is there a cost to discuss my rights with the firm?

There is no cost or obligation to discuss your rights with Bragar Eagel & Squire.

Last updated: Oct 8, 2025